Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMD-477 and Farxiga in Type 1 Diabetes
NCT04545411Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Feb 2021
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of volagidemab in type 1 diabetes mellitus (T1D), sponsored by University of California, San Diego. Started Feb 2021; status: completed.
02
Drugs
volagidemab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04545411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04545411.